EU Clinical Trials Framework for Cannabis Research

Clinical research on cannabis and cannabinoids in the European Union operates under the EU Clinical Trials Regulation (Regulation (EU) No 536/2014), which replaced the previous Clinical Trials Directive and established a harmonized framework for conducting clinical trials across member states through the Clinical Trials Information System (CTIS). For cannabis researchers, this regulation provides both opportunities and challenges — the harmonized framework simplifies multi-country trial coordination, but the controlled substance status of cannabis adds layers of complexity around supply, storage, and reporting that do not apply to most investigational medicinal products. The scientific case for cannabis clinical research in Europe has strengthened considerably, driven by growing patient demand for evidence-based medical cannabis treatments, regulatory pressure from health technology assessment (HTA) bodies requiring clinical evidence for reimbursement decisions, and the commercial incentive for pharmaceutical companies to develop authorized cannabis-based medicinal products. Key research areas include cancer-related pain and nausea, neurological conditions (particularly epilepsy and multiple sclerosis), chronic pain syndromes, anxiety and PTSD, and inflammatory conditions. However, the number of completed high-quality clinical trials remains limited compared to the scale of medical cannabis prescribing across Europe, creating what researchers describe as an evidence gap that hampers both clinical practice and regulatory decision-making.

The Clinical Trials Regulation (EU) No 536/2014 introduced a single submission portal (CTIS) for clinical trial applications across all EU member states, replacing the fragmented national application processes under the previous directive. For cannabis trials, this means researchers can submit a single application to conduct a multi-country trial, with coordinated assessment by the involved member states. The application must include the investigational medicinal product dossier (IMPD) — for cannabis, this requires comprehensive quality documentation including manufacturing process descriptions, analytical specifications for cannabinoid content (THC, CBD, and other relevant cannabinoids), impurity profiles, stability data, and evidence of GMP-compliant manufacturing. The IMPD requirements are particularly demanding for whole-plant cannabis preparations, as the complexity of the phytochemical matrix (containing hundreds of cannabinoids, terpenes, and flavonoids) makes quality characterization more challenging than for single-molecule pharmaceutical compounds.

Securing the supply of investigational cannabis product is often one of the most complex aspects of trial planning. The investigational medicinal product (IMP) must be manufactured under GMP conditions by an authorized manufacturer, and the supply chain must comply with controlled substance regulations in every country where the trial is conducted. Researchers must obtain import and controlled substance handling licenses from each national competent authority, maintain secure storage facilities at trial sites, and implement rigorous accountability procedures for tracking every gram of cannabis dispensed, returned, or destroyed. The practical burden of these requirements has led some researchers to design trials using commercially available pharmaceutical cannabis preparations (such as Bedrocan's standardized products or GW Pharmaceuticals' formulations) rather than developing novel IMP formulations, as this leverages existing GMP-certified supply chains.

Ethics committee approval and informed consent processes for cannabis trials face unique considerations. Ethics committees in some EU countries may apply heightened scrutiny to cannabis research due to the substance's historical classification and perceived stigma, even when the proposed research is scientifically rigorous. Informed consent documents must clearly explain the nature of the investigational product, including the psychoactive effects of THC-containing preparations, potential for cannabis use disorder, interaction risks with other medications, and implications for driving and workplace drug testing. Regulatory requirements for cannabis-specific safety monitoring may include additional assessments of abuse potential, cognitive function, and psychiatric symptoms that would not typically be required for other investigational products. Data reporting to the CTIS database must include cannabis-specific adverse event coding, and any suspected unexpected serious adverse reactions (SUSARs) must be reported within strict timelines.

Key areas of active clinical research on cannabis in Europe include pain management (particularly the CANNA-PAIN and similar multi-center trials), epilepsy (building on the evidence base established by Epidiolex/Epidyolex), oncology supportive care (anti-emetic and appetite stimulation applications), neurological conditions (spasticity in multiple sclerosis, where Sativex/Nabiximols has established a precedent), and mental health conditions (PTSD, anxiety, and sleep disorders). The European Medicines Agency has issued scientific guidance on the quality requirements for cannabis-based medicines, and several member state medicines agencies — particularly in Germany, the Netherlands, and Denmark — have established dedicated cannabis research advisory pathways. Academic institutions including the University of Leiden, the University Medical Center Hamburg-Eppendorf, and King's College London maintain active cannabinoid research programs. The trend is toward larger, more rigorous randomized controlled trials that can generate the level of evidence required by HTA bodies for formal reimbursement recommendations.